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Abstract
Rat maternal behavior is a complex social behavior. Most antipsy-
chotic drugs disrupt active maternal responses (e.g., pup retrieval, 
pup licking and nest building). Our previous work shows that typi-
cal antipsychotic haloperidol disrupts maternal behavior by blocking 
dopamine D2 receptors, whereas atypical clozapine works by block-
ing 5-HT2A/2C receptors. The present study used c-Fos immunohis-
tochemistry technique, together with pharmacological tools and be-
havioral observations, and delineated the neuroanatomical bases of 
the disruptive effects of haloperidol and clozapine. Postpartum fe-
male rats were treated with haloperidol (0.2 mg/kg sc) or clozap-
ine (10.0 mg/kg sc), with or without pretreatment of quinpirole (a 
selective dopamine D2/D3 agonist, 1.0 mg/kg sc) or 2,5-dimethoxy-
4-iodo-amphetamine (DOI, a selective 5-HT2A/2C agonist, 2.5 mg/
kg sc). They were then sacrificed 2 h later after a maternal behavior 
test was conducted. Brain regions that have been previously impli-
cated in the regulation of rat maternal behavior and/or in the anti-
psychotic action were examined. Behaviorally, both haloperidol and 
clozapine disrupted pup retrieval, pup licking and nest building. 
Pretreatment of quinpirole, but not DOI, reversed the haloperidol-
induced disruptions. In contrast, pretreatment of DOI, but not quin-
pirole, reversed the clozapine-induced deficits. Neuroanatomically, 
the nucleus accumbens (both the shell and core), dorsolateral stri-
atum and lateral septum showed increased c-Fos expression to the 
treatment of haloperidol. In contrast, the nucleus accumbens shell 
showed increased expression of c-Fos to the treatment of clozapine. 
More importantly, pretreatment of quinpirole and DOI produced op-
posite response profiles in the brain regions where haloperidol and 
clozapine had an effect. Based on these findings, we concluded that 
haloperidol disrupts active maternal behavior primarily by blocking 
dopamine D2 receptors in a neural circuitry involving the nucleus ac-
cumbens, dorsolateral striatum and lateral septum. In contrast, clo-
zapine appears to disrupt maternal behavior mainly by blocking se-
rotonin 5-HT2A/2C receptors in the nucleus accumbens shell.
Keywords: quinpirole, DOI, c-Fos, nucleus accumbens, antipsychotic 
drugs, rat maternal behavior
Abbreviations: APDs, antipsychotic drugs; CLZ, clozapine; DLSt, 
dorsolateral striatum; DOI, 2,5-dimethoxy-4-iodo-amphetamine; 
Fos-I, Fos-immunoreactivity; HAL, haloperidol; LSv, ventral part of 
lateral septal nucleus; MeA, medial amygdaloid nucleus; mPFC, me-
dial prefrontal cortex; MPOA, medial preoptic area; NAc, nucleus 
accumbence core; NAs, nucleus accumbence shell; NGS, normal 
goat serum; PBS, phosphate-buffered saline; QUI, quinpirole; vBST, 
ventral bed nucleus of the stria terminalis
◘      ◘      ◘
Animal models are valuable tools for the study of mecha-
nisms of action of antipsychotic drugs (APDs) (Lieberman et 
al., 2008). In recent years, we have used rat maternal behavior 
to investigate the behavioral and neurochemical mechanisms 
of action of APDs. We chose this model because it is a com-
plex social behavior system that cuts across mammalian spe-
cies and shares many direct features with human mothering 
behaviors (Fleming and Corter, 1988; Rosenblatt, 1989). Thus, 
it reflects the complex and multi-dimensional actions of APDs 
better than other simple models.
Behaviorally, we and others have shown that clinically com-
parable doses of haloperidol (HAL), clozapine (CLZ), risper-
idone, quetiapine, amisulpride and aripiprazole (~50%–80% 
dopamine D2 occupancy) disrupt active components of mater-
nal behavior, such as pup retrieval, pup licking and nest build-
ing (Li et al., 2004; Stern and Keer, 1999; Zhao and Li, 2009a). 
We found that pup separation, which putatively increases ma-
ternal motivation, is able to reverse some of the maternal be-
havior deficits caused by HAL and CLZ (Zhao and Li, 2009a), 
suggesting that suppression of maternal motivation is one im-
portant behavioral mechanism underlying the disruptive ef-
fects of APDs. Neurochemically, we recently reported an inter-
esting double dissociation of the receptor mechanisms between 
HAL- and CLZ-induced maternal behavior deficits (Zhao and 
Li, 2009b). We found that pretreatment of quinpirole (a selec-
tive dopamine D2/D3 agonist), but not 2,5-dimethoxy-4-iodo-
amphetamine (DOI, a selective 5-HT2A/2C agonist), dose-de-
pendently reversed the HAL-induced disruptions. In contrast, 
pretreatment of DOI, but not quinpirole, dose-dependently re-
versed the CLZ-induced deficits. This study suggests that HAL 
disrupts maternal behavior primarily by blocking dopamine 
D2 receptors, whereas CLZ works primarily by blocking 5-
HT2A/2C receptors.
The present study represented our efforts to investigate the 
neuroanatomical basis of action of antipsychotics using the rat 
maternal behavior model. The traditional approach in this field 
is to examine brain regions that show drug-induced changes 
using biomarkers such as c-Fos (a protein product of immedi-
ate-early gene c-fos) (Mo et al., 2005; Natesan et al., 2006; Rob-
ertson and Fibiger, 1992; Robertson et al., 1994). Although it is 
straightforward, this approach has two problems. The first is 
that it fails to connect a drug’s behavioral effects with its neu-
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ronal effects. In a typical study, animals are injected with an 
antipsychotic drug in their home cages, and sacrificed 2 h later 
for brain analysis. Animal behavior and behavioral effects of 
the drug treatment are generally ignored. Thus, it is impossi-
ble to determine whether the identified brain regions that show 
changes of c-Fos expression are the ones that mediate the be-
havioral effects of the drug. This issue is further complicated 
by the fact that animal behavior itself can also induce brain 
changes as indexed by c-Fos expression. For example, mater-
nal behavior can stimulate c-Fos expression in the medial pre-
optic area (MPOA), the ventral bed nucleus of the stria termi-
nalis (vBST) and the nucleus accumbens (Fleming et al., 1994; 
Lonstein and De Vries, 2000; Lonstein et al., 1998; Lonstein et al., 
2000; Numan and Insel, 2003; Numan and Numan, 1994; Nu-
man and Numan, 1995; Numan et al., 1998). The second prob-
lem is that it does not take the neurochemical mechanisms of 
different APDs into consideration. As mentioned above, al-
though both HAL and CLZ disrupt active maternal responses, 
they do so via blocking dopamine D2 and 5-HT2A/2C receptors, 
respectively. It is quite possible that HAL and CLZ may induce 
similar changes in c-Fos expression in the same brain regions 
through distinct receptor mechanisms. Simply relying on the 
drug-induced c-Fos expression does not guarantee a correct 
identification of receptor-mediated neuroanatomical basis of a 
drug action.
In the present study, we used the c-Fos immunohistochem-
istry technique, together with pharmacological tools and be-
havioral observations, to delineate the neural circuitries upon 
which HAL and CLZ act to achieve their disruptive effects on 
rat maternal behavior. Rats were treated with HAL (0.2 mg/
kg sc) or CLZ (10.0 mg/kg sc), with or without pretreatment 
of QUI (1.0 mg/kg sc) or DOI (2.5 mg/kg sc). They were then 
sacrificed 2 h later after maternal behavior was tested. We con-
sidered a brain region to be part of the neural circuitry of HAL 
or CLZ only if it meets the following three criteria: (1) it shows 
sensitive c-Fos response to the treatment of HAL or CLZ; (2) it 
shows sensitive c-Fos response to the reversal effect of pretreat-
ment of QUI on HAL or DOI on CLZ; and (3) it does not show 
or shows little c-Fos response to the pretreatment of DOI on 
HAL or QUI on CLZ. This approach ensured that the brain re-
gions identified are behaviorally and neurochemically relevant 
to the specific action of HAL and CLZ.
Experimental procedures
Subjects and housing
Naive pregnant female Sprague–Dawley rats (between gesta-
tional days 13–15 upon arrival to the animal facility) obtained 
from Charles River Inc. (Portage, MI) were housed individually in 
48.3×26.7×20.3 cm3 transparent polycarbonate cages under a 12-h 
light/dark cycle (lights on at 6:30 am) and temperature-controlled 
(22 ± 1 °C) condition, and were given free access to standard lab-
oratory rat chow and water. All behavioral tests were performed 
in the light phase between 9:00 am and 4:00 pm. All animal ma-
nipulations were reviewed and approved by the University of Ne-
braska Institutional Animal Care and Use Committee, and were 
carried out in compliance with the National Institutes of Health 
Guide for the Care and Use of Laboratory Animals. The number of 
animals used was minimized to the level that would provide suffi-
cient statistical power, and every effort was made to minimize the 
suffering of the animals.
Drugs and choices of doses
Haloperidol (HAL, 5.0 mg/ml ampoules, Sicor Pharmaceuticals, 
Inc, Irvine, CA, USA) was diluted with sterile water. Clozapine 
(CLZ, a gift from NIMH drug supply program) was dissolved in 
1.0% glacial acetic acid in distilled water. Quinpirole (QUI) and 
DOI (RBI-Sigma, Natick, MA, USA) were dissolved in 0.9% saline. 
HAL (0.2 mg/kg), CLZ (10.0 mg/kg), QUI (1.0 mg/kg), DOI (2.5 
mg/kg) and vehicle (water or saline) were all administered s.c. 
in a volume of 1.0 ml/kg body weight. Choices of drug doses for 
HAL and CLZ were based on our previous studies showing that 
at the chosen doses, HAL and CLZ reliably disrupt active compo-
nents of maternal behavior (Li et al., 2004). The doses of QUI and 
DOI were chosen based on our recent study showing that QUI 1.0 
mg/kg completely reversed the HAL-induced disruptions of pup 
retrieval, pup licking and nest building; and DOI 2.5 mg/kg com-
pletely reversed the CLZ-induced disruptions of pup retrieval and 
licking (Zhao and Li, 2009b). We employed the same drug injec-
tion regimen and behavioral observation procedure as detailed in 
our recent study (Zhao and Li, 2009b), so that we could not only 
replicate our previous study but also use the behavioral effects as a 
guide to identify the relevant neural substrates underlying action 
of HAL and CLZ (as indexed by c-Fos expression).
Basic experimental procedure
Starting 2 or 3 days prior to the first possible expected parturition 
date, the subjects were monitored every morning for signs of par-
turition. Once the dam was found with pups in the morning (that 
day was designated as Day 1 postpartum), the mother was trans-
ferred into a clean cage with wood shavings for bedding. Two 
shredded paper towels were also provided as additional nesting 
material. The litter was culled to eight pups (four males and four 
females with the most visible milk bands). Maternal behavior tests 
were conducted on one day between Day 6 and 8 postpartum.
Maternal behavior test
The basic procedure was identical to that described by Zhao and Li 
(2009b). A total of 54 postpartum rats were randomly divided into 
the following nine groups (n=6/group) using a full factorial design 
(three pretreatment conditions×three antipsychotic conditions): 
VEH+VEH (sterile water or saline), VEH+HAL, QUI-1.0+HAL, 
DOI-2.5+HAL, QUI-1.0+VEH, VEH+CLZ, DOI-2.5+CLZ, QUI-
1.0+CLZ, DOI-2.5+VEH. On the drug test day (one day on either 
Postpartum Day 6, 7, or 8), all subjects were tested twice, with the 
first maternal behavior test starting at 30 min prior to the drug 
(e.g., HAL, CLZ, QUI or DOI) or vehicle injection (i.e., baseline) 
and the second test occurring at 120 min after drug or vehicle injec-
tion. QUI, DOI or vehicle was injected s.c. twice with the first injec-
tion at 10 min before and the second at 50 min after the HAL, CLZ 
or vehicle injection, as was done in Zhao and Li (2009b).
In each test (8 min), using a laptop computer equipped with 
an event recording program (JWatcher, http://www.jwatcher.
ucla.edu), we recorded the frequency or duration of various com-
ponents of maternal behavior. Each test started by removing the 
eight pups from the dam and destroying the nest. Ten seconds 
later, the pups were returned to the corner of the cage diagonal to 
the nest site or dam sleeping corner. When the subject picked up 
a pup in her mouth and carried it back to the nest site, it was re-
ferred to as a successful pup retrieval. The total number of pups 
retrieved was recorded. The occurrence of other behaviors was 
also recorded, including pup nursing behavior (a rat position-
ing herself over the pups with legs splayed to accommodate the 
pups, including hover, high and low crouching over postures), 
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pup licking (a female rat placing its tongue on the anogenital area 
and the rest of a pup’s body), nest building (a rat picking up nest-
ing material in her mouth and transporting it back to the nest site 
or pushing the material with her forepaws toward the nest site). 
At the conclusion of the test, any unretrieved pups were returned 
to the nest site.
c-Fos immunohistochemistry
Immediately after the second maternal behavior test, all rats were 
anesthetized with a lethal dose of sodium pentobarbital (100.0 mg/
kg, Sigma-Aldrich, St. Louis, MO, USA) and then perfused trans-
cardially with ice-cold 0.9% saline followed by 4% paraformalde-
hyde in 0.1 M phosphate buffer (PB) containing 0.2% picric acid 
at pH 7.4. Brains were rapidly removed from the skulls and post-
fixed in the same fixative overnight at 4 °C. They were then trans-
ferred to 30% sucrose in 0.1 M PB until settled. Coronal sections 
at a thickness of 40 μm were cut on a freezing microtome and col-
lected in 0.02 M phosphate-buffered saline (PBS) containing 0.1% 
sodium azide until processing. Procedures for c-Fos immunohis-
tochemistry followed the protocol by Zhao et al. (2007) with slight 
modifications. Sections were pre-blocked for 1 h with 10% normal 
goat serum (NGS) and 0.3% Triton X-100 in 0.02 M PBS, incubated 
for 30 min with 1.5% hydrogen peroxide and 50% methanol to in-
hibit endogenous peroxidase. They were washed with wash buf-
fer (0.02 M PBS containing 0.05% NGS and 0.3% Triton X-100) and 
then incubated with a rabbit polyclonal anti-c-Fos (Ab-5, PC38) an-
tibody raised against residues 4–17 of human c-Fos (1:20000 dilu-
tion, Calbiochem, CA, USA) in PBS containing 0.3% Triton X-100, 
1% NGS and 1% blocking reagent for 48 h at 4 °C. After the pri-
mary immunoreaction, sections were rinsed with wash buffer and 
incubated with a biotinylated goat anti-rabbit secondary antibody 
(1:200 dilution, Vector Laboratories, Burlingame, CA, USA) in PBS 
containing 1% NGS for 2 h at RT. They were rinsed with PBS and 
processed with avidin–biotin horseradish peroxidase complex 
(1:200 dilution, Vectastain Elite ABC Kit, Vector Laboratories). The 
immunoreaction was visualized with peroxidase substrate (DAB 
Substrate Kit for Peroxidase, Vector Laboratories). After staining, 
sections were mounted on gelatin-coated slides, air-dried, dehy-
drated in a graded series of alcohols, cleared in xylene and cov-
erslipped with permount. As a control, the primary antibody was 
substituted with normal rabbit serum. No corresponding nucleus 
or cytoplasm was immunostained in the control.
Fos-immunoreactive (Fos-I) cell counting
Microscopic images were captured with a digital camera (INFIN-
ITY lite, Canada) furnished with an Olympus CX41RF microscope 
(Japan) using ×10 objective lens. The number of Fos-I cells charac-
terized by clearly labeled nuclei was counted unilaterally in three 
serial sections which were anatomically well-matched across the 
treatment groups. The brain regions analyzed included the neu-
ral sites that were either implicated in the action of antipsychotic 
drugs [e.g., the medial prefrontal cortex (mPFC), nucleus accum-
bence shell (NAs), nucleus accumbence core (NAc), dorsolateral 
striatum (DLSt), ventral part of lateral septal nucleus (LSv)], and/
or in the regulation of maternal behavior [e.g., MPOA, ventral bed 
nucleus of the stria terminalis (vBST), medial amygdaloid nucleus 
(MeA) and nucleus accumbens shell and core] (Li and Fleming, 
2003a; Li and Fleming, 2003b; Numan et al., 2005). The levels of 
brain slices were Bregma 3.00 mm for mPFC, 1.80 mm for NAs, 
NAc, DLSt and LSv, −0.24 for MPOA and vBST, −2.64 mm for 
MeA according to Paxinos and Watson (2007) (Figure 1). With the 
help of ImageJ software (developed at the US National Institutes 
of Health), cell counts were made within a 680×510 μm2 unit area 
of each interest region by an experimenter blind to the treatment 
condition. The images were thresholded and then analyzed. In a 
given area from distinct treatments, the images were thresholded 
to the same value by means of eliminating background and noise 
staining to ensure that the Fos-I cells were selected. The number of 
Fos-I nuclei of a given brain region from unilateral sites per rat was 
averaged. The values from six rats of each treatment group were 
averaged to obtain the final mean ± SEM.
Statistical analysis
Statistical analyses were performed using SPSS 17.0 software (SPSS 
Inc., Chicago, IL, USA). Maternal behavior and c-Fos data were 
presented as mean ± SEM and analyzed using two-way analysis 
of variance (ANOVA) with pretreatment (three levels: VEH, QUI-
1.0, DOI-2.5)×antipsychotic treatment (three levels: VEH, HAL, 
CLZ) as between-subject factors. When the overall significant ef-
fects were detected, multiple group differences were assessed us-
ing simple main effect tests (one-way ANOVA) followed by Fish-
er’s protected least significant difference (PLSD) test for pairwise 
comparisons of means. A conventional two-tailed level of signifi-
cance at the 0.05 level was required.
Figure 1. Schematic representation of the forebrain regions (black 
boxed areas) in which the c-Fos immunoreactive cells were 
counted. Distance from bregma in the rostrocaudal planes is indi-
cated. Drawings were modified from Paxinos and Watson (2007). 
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Results
Overall effects of drug pretreatment and antipsychotic treat-
ment on maternal behavior
There was no significant effect of drug pretreatment and anti-
psychotic treatment on the baseline maternal behavior. For the 
maternal behavior data obtained at 2 h post-antipsychotic in-
jection, two-way ANOVAs revealed a significant interaction 
between the pretreatment and antipsychotic treatment on pup 
retrieval [F(4,45)=20.05, P<0.001], pup licking [F(4,45)=5.06, 
P=0.002], nest building [F(4,45)=26.01, P<0.001], and pup nurs-
ing [F(4,45)=10.56, P<0.001], suggesting that the disruptive ef-
fects of antipsychotic treatment on maternal behavior were 
modulated by QUI and DOI pretreatment.
HAL or CLZ treatment disrupted various components of ma-
ternal behavior
Consistent with our previous findings (Li et al., 2004; Zhao and 
Li, 2009a; Zhao and Li, 2009b), a single injection of HAL or CLZ 
disrupted various components of maternal behavior. As can be 
seen in Figure 2 and Figure 3,, at 2 h after antipsychotic adminis-
tration, the HAL- or CLZ-treated rats retrieved fewer pups into 
the nest site, spent less time licking their pups and reconstruct-
ing the nest in comparison to the vehicle-treated ones (HAL: P 
values <0.001 for pup retrieval and nest building, P=0.027 for 
pup licking; CLZ: P values <0.001 for pup retrieval and nest 
building, P=0.024 for pup licking). HAL treatment had little ef-
fect on pup nursing, whereas CLZ significantly decreased pup 
nursing activity (HAL: P>0.10; CLZ: P=0.018).
QUI or DOI treatment alone also disrupted various compo-
nents of maternal behavior
In comparison to the VEH+VEH rats, the QUI- or DOI-treated 
ones retrieved fewer pups into the nest (QUI: P=0.008; DOI: 
P<0.001; Figures 2A and 3A). They also spent less time on 
licking (QUI: P=0.026; DOI: P=0.024) and nursing pups (QUI: 
P=0.002; DOI: P=0.001), and on building the nest (both P values 
<0.001) (Figures 2B–D and 3B–D), suggesting that QUI or DOI 
treatment itself has a disruptive effect on various components 
of maternal behavior.
Pretreatment of QUI attenuated HAL-induced disruptions of 
maternal behavior, but failed to improve CLZ-induced ones
Pretreatment of QUI significantly improved the HAL-induced 
maternal behavior deficits. In comparison to the VEH+HAL 
rats, the QUI+HAL ones retrieved more pups (P<0.001), spent 
more time on pup licking (P=0.049) and nest building (P<0.001) 
(Figure 2A–C). Furthermore, the reversal effect of QUI on these 
behaviors appeared to reach the normal level as there was 
no significant difference between the QUI+HAL group and 
VEH+VEH group. In contrast, QUI had little effect on CLZ-in-
duced maternal behavior disruptions. There were no signifi-
cant group differences between the QUI+CLZ group and the 
VEH+CLZ group (all P values >0.10) (Figure 3A–D).
Figure 2. Effects of pretreatment of quinpirole (QUI) or DOI on HAL-induced maternal behavior deficits in the postpartum female rats. Pup re-
trieval (A), pup licking (B), nest building (C) and pup nursing (D) were tested at baseline and at 120 min after injection of HAL or vehicle. HAL dis-
rupted all active maternal responses, but leaving nursing behavior intact. Quinpirole, but not DOI, attenuated the HAL-induced disruptions of ma-
ternal behavior (A–C). Quinpirole itself also disrupted various components of maternal behavior (A–D). Each bar represents the mean ± SEM of 
duplicate determinations from six rats. * P<0.05 versus VEH+VEH control; # P<0.05 versus VEH+HAL group. 
c-f o s i d o f n eur o a n a to mi c al s i tes f o r  h a lo p er i d o l an d c lo z ap i n e d i s r up ti o n   1047
Pretreatment of DOI attenuated CLZ-induced maternal be-
havior disruptions, but failed to improve HAL-induced ones
Pretreatment of DOI significantly alleviated the CLZ-induced 
maternal behavior deficits. In comparison to the VEH+CLZ 
rats, the DOI+CLZ ones retrieved more pups (P=0.001) and 
spent more time licking their pups (P=0.015) (Figure 3A, B). 
There were also no significant group differences between the 
DOI+CLZ and VEH+VEH groups in these two behaviors (both 
P values >0.10), suggesting that the reversal effect of DOI was 
complete. Pretreatment of DOI also tended to improve the CLZ-
induced disruptions of nest building and pup nursing; how-
ever, this effect did not reach the significant level (nest build-
ing: P=0.31; pup nursing: P=0.28 vs. VEH+CLZ group) (Figure 
3C, D). In contrast, pretreatment of DOI was ineffective in im-
proving the HAL-induced maternal behavior deficits. There 
were no significant differences between the DOI+HAL group 
and the VEH+HAL group (all P values >0.10; Figure 2A–C).
Overall effects of drug pretreatment and antipsychotic treat-
ment on c-Fos expression
Of the eight brain regions examined, six (mPFC, NAs, NAc, 
DLSt, LSv and vBST) showed a significant pretreatment effect 
[mPFC: F(2,45)=60.24, P<0.001; NAs: F(2,45)=374.23, P<0.001; 
NAc: F(2,45)=191.13, P<0.001; DLSt: F(2,45)=774.41, P<0.001; 
LSv: F(2,45)=8.74, P=0.001; vBST: F(2,45)=10.59, P<0.001], a sig-
nificant antipsychotic treatment effect [mPFC: F(2,45)=10.98, 
P<0.001; NAs: F(2,45)=195.74, P<0.001; NAc: F(2,45)=538.23, 
P<0.001; DLSt: F(2,45)=4506.09, P<0.001; LSv: F(2,45)=35.75, 
P<0.001; vBST: F(2,45)=5.69, P=0.006], and a significant inter-
action between the two factors [mPFC: F(4,45)=19.16, P<0.001; 
NAs: F(4,45)=107.70, P<0.001; NAc: F(4,45)=60.22, P<0.001; 
DLSt: F(4,45)=678.16, P<0.001; LSv: F(4,45)=8.64, P<0.001; 
vBST: F(4,45)=9.77, P<0.001]. The MPOA showed only a signif-
icant pretreatment effect [F(2,45)=32.04, P<0.001], but no sig-
nificant antipsychotic treatment effect or interaction. The only 
brain region that did not show any significant effect was the 
MeA (see representative c-Fos staining images in Figure 4 and 
Figure 5, Table 1).
HAL and CLZ treatment induced different patterns of c-Fos 
expression in the forebrain regions
Consistent with the previous reports on male rats (Binder et 
al., 2004; MacGibbon et al., 1994; Merchant and Dorsa, 1993; 
Nguyen et al., 1992; Robertson et al., 1994), HAL and CLZ in-
duced different patterns of c-Fos expression in the forebrain 
in postpartum female rats. In comparison to the vehicle treat-
ment, HAL significantly increased c-Fos expression in the NAs, 
NAc, DLSt and LSv (all P values <0.001; Figures 4D and 6B–
D), but had little effect in the mPFC, MPOA, vBST and MeA 
(Figures 5D and 6A, Table 1). CLZ also increased c-Fos expres-
sion in the NAs and LSv (both P values <0.001; Figures 4G and 
6B, D). In addition, it also significantly increased c-Fos expres-
sion in the mPFC (P<0.001, Figure 6A), as well as in the vBST 
(P<0.001, Table 1), an area known to be critically involved in 
the regulation of maternal behavior, but failed to alter c-Fos ex-
pression in the NAc, DLSt, MPOA and MeA (Figures 5G and 
6B, C, Table 1).
Figure 3. Effects of pretreatment of quinpirole (QUI) or DOI on CLZ-induced maternal behavior deficits in the postpartum female rats. Pup re-
trieval (A), pup licking (B), nest building (C) and pup nursing (D) were tested at baseline and at 120 min after injection of CLZ or vehicle. CLZ dis-
rupted various components of maternal behavior. DOI, but not quinpirole improved the CLZ-induced disruptions of pup retrieval and pup licking, 
but had less effect on nest building and pup nursing. In contrast, quinpirile failed to improve any maternal behavior deficit induced by CLZ (A–D). 
DOI itself also disrupted various components of maternal behavior (A–D). Each bar represents the mean ± SEM of duplicate determinations from 
six rats. * P<0.05 versus VEH+VEH control; # P<0.05 versus VEH+CLZ group. 
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QUI and DOI treatment alone also altered c-Fos expression 
in the forebrain regions
QUI alone significantly increased c-Fos expression in the mPFC 
and vBST (both P values <0.001; Figure 6A, Table 1), while it 
reduced c-Fos expression in the NAs and NAc (both P values 
<0.001; Figures 4B and 6B). QUI did not alter c-Fos expression 
in the DLSt, LSv, MPOA and MeA (Figures 5B and 6C, D, Ta-
ble 1). DOI alone significantly increased c-Fos expression in 
the mPFC, NAs, NAc, MPOA and vBST (mPFC: P<0.001; NAs: 
P<0.001, NAc: P<0.001; MPOA: P=0.001; vBST: P<0.001; Fig-
ures 4C, 5C and 6A, B, Table 1), but had little effect in the DLST, 
LSv and MeA (Figure 6C, D, Table 1).
The individual effects of HAL, CLZ, QUI and DOI treat-
ment on the c-Fos expression in the eight brain regions are 
summarized in Table 2. We calculated the percent changes of 
drug treatment relative to the vehicle treatment. It appears that 
the nucleus accumbens, especially the shell region, is the com-
mon site on which all four drugs act. CLZ, QUI and DOI, but 
not HAL, also increased the c-Fos expression in the mPFC and 
vBST. In addition, only HAL increased the c-Fos expression in 
the DLSt, consistent with its EPS profile in the clinic.
Pretreatment of QUI significantly reduced HAL-induced c-
Fos increase in the NAs, NAc, DLSt and LSv, but also reduced 
CLZ-induced c-Fos increase in the NAs
In comparison to HAL treatment alone (i.e., VEH+HAL), pre-
treatment of QUI (i.e., QUI+HAL) significantly reduced the 
HAL-induced c-Fos increase in the NAs, NAc, DLSt and LSv 
(all P values <0.001; Figures 4E and 6B–D). In contrast, pretreat-
ment of QUI only reduced CLZ-induced c-Fos increase in the 
NAs (P<0.001; Figures 4H and 6B), but had no effect on CLZ-
induced c-Fos increase in the mPFC, LSv and vBST (Figure 6A, 
D, Table 1).
Pretreatment of DOI significantly reduced CLZ-induced c-Fos 
increase in the NAs, but also reduced HAL-induced increase in 
the NAs, NAc and DLSt
In comparison to CLZ treatment alone (i.e. VEH+CLZ), pre-
Figure 4. Photomicrographs of immunohistochemistry showing c-Fos expression in the nucleus accumbens shell. Note that in comparison to the 
vehicle treatment (A), quinpirole reduced the number of c-Fos immunoreactive cells (B), whereas DOI, HAL and CLZ significantly increased the c-
Fos immunoreactive cells (C, D, G). Pretreatment with both quinpirole and DOI significantly reduced HAL-induced increase in c-Fos expression, 
although quinpirole had a more stronger effect than DOI (E, F). Similarly, both QUI and DOI significantly reduced CLZ-induced increase in c-Fos 
expression, while the effect of quinpirole was more prominent than DOI (H, I). Scale bar=100 μm. 
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treatment of DOI reduced CLZ-induced c-Fos increase in the 
NAs (Figures 4I and 6B, P<0.001). However, DOI did not alter 
CLZ-induced c-Fos increase in the mPFC, LSv and vBST (Fig-
ure 6A, D, Table 1). The combined DOI and CLZ treatment pro-
duced an increased c-Fos expression in the MPOA, although 
CLZ itself did not alter c-Fos expression in this region (P<0.001; 
Figure 5I, Table 1).
In comparison to HAL treatment alone (i.e. VEH+HAL), 
pretreatment of DOI (i.e. DOI+HAL) significantly reduced the 
number of HAL-induced c-Fos increase in the NAs, NAc and 
DLSt (all P values <0.001; Figures 4F and 6B, C). This effect was 
similar to that of the pretreatment effect of QUI. Although HAL 
treatment alone did not alter c-Fos expression in the mPFC and 
MPOA, the combined DOI and HAL treatment significantly in-
creased c-Fos expression in these two regions (both P values 
<0.001; Figures 5F and 6A, Table 1), suggesting that this in-
creasing effect was primarily due to DOI, consistent with the 
finding that DOI treatment alone increased c-Fos expression in 
both regions (see Figures 5C and 6A, Table 1).
The above analysis simply examined the direct effects of 
QUI and DOI pretreatment on HAL- and CLZ-induced c-Fos 
expression. It failed to take into consideration the intrinsic ef-
fects of QUI and DOI treatment alone on c-Fos expression. For 
example, because QUI or DOI itself had an opposite effect on 
c-Fos expression in the NAs (i.e., QUI reduced, while DOI in-
creased c-Fos expression in the NAs), even though both drugs 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 1.  Number of c-Fos immunoreactive cells in the MPOA, vBST, 
and MeA of postpartum female rats
Groups                     N        MPOA                         vBST                MeA
VEH + VEH  96 ± 1.6 78 ± 1.9 76 ± 4.1
VEH+HAL 6 103 ± 3.5 89 ± 5.3 78 ± 2.6
QUI-1.0+HAL 6 94 ± 4.1 71 ± 2.5** 75 ± 2.6
DOI-2.5+HAL 6 134 ± 9.5*, *** 98 ± 5.0* 78 ± 3.1
QUI-1.0+VEH 6 104 ± 2.7 100 ± 3.9* 75 ± 2.7
VEH+CLZ 6 91 ± 2.0 99 ± 2.3* 81 ± 5.8
DOI-2.5+CLZ 6 124 ± 8.0*, *** 97 ± 2.9* 80 ± 2.5
QUI-1.0+CLZ 6 105 ± 2.7 92 ± 4.8* 78 ± 3.5
DOI-2.5+VEH 6 123 ± 4.2*,*** 104 ± 2.7* 72 ± 2.9
Data are presented as mean ± SEM.
 *  P < 0.05 relative to the VEH+VEH group. 
 **  P < 0.05 relative to the VEH+HAL group. 
***  P < 0.05 relative to the VEH+CLZ group.
Figure 5. Photomicrographs of immunohistochemistry showing c-Fos expression in the medial preoptic area. Note that in comparison to the ve-
hicle treatment (A), only DOI, but not quinpirole, HAL or CLZ, produced a significant increase in c-Fos expression in the MPOA (B, C, D, G). 
DOI pretreatment significantly increased c-Fos expression, while quinpirole had little effect in both HAL- and CLZ-treated rats (E, F, H, I). Scale 
bar=100 μm. 
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reduced HAL-induced c-Fos increase in the NAs, the na-
ture of their impact would be different. To account for this 
intrinsic difference between QUI and DOI and to delineate 
a more accurate behavioral profile of QUI and DOI pretreat-
ment on HAL and CLZ, we developed the following formulas 
and used the “group mean” (number of c-Fos immunoreac-
tive cells) to calculate the overall pretreatment impact of QUI 
and DOI on HAL or CLZ for each brain region (using HAL as 
an example):
Pretreatment impact of QUI on HAL
= 
      [(QUI – 1.0 + HAL)  –  (VEH + HAL)] ÷ (VEH + HAL)
[(QUI  –  1.0 + HAL)  –  (VEH + VEH)] ÷ (VEH + VEH)
Pretreatment of DOI on HAL
=
    [(DOI  –  2.5 + HAL)  –  (VEH + HAL)] ÷ (VEH + HAL)
[(DOI  –  2.5 + VEH)  –  (VEH + VEH)] ÷ (VEH + VEH)
Table 2.  Relative percent change of effects of drug treatments on c-Fos expression
Treatment mPFC NAs NAc DLSt LSv MPOA vBST MeA  
VEH+VEH – – – – – – – –  
VEH+HAL – ↑↑↑ ↑↑↑ ↑↑↑ ↑ – – –  
VEH+CLZ ↑ ↑↑ – – ↑ – ↑ –  
QUI-1.0+VEH ↑ ↓ ↓ – – – ↑ –  
DOI-2.5+VEH ↑ ↑↑ ↑ – – ↑ ↑ – 
–, no significant change; ↑ or ↓, increase or decrease more than 20% but less than 100%; ↑↑, increase more than 100% but less than 200%; ↑↑↑, in-
crease more than 200%. Percent change was calculated by subtracting the cell number in the vehicle control group (V) from the cell number in 
the treatment groups (T), dividing by cell number in the vehicle control group, and multiplying by 100 [(T – V)/V × 100].
Figure 6. Effects of HAL, CLZ, QUI or DOI treatment alone, and the combined treatments of these drugs on HAL- or CLZ-induced c-Fos expression 
in the mPFC (A), NAs, NAc (B), DLSt (C) and LSv (D). Each bar represents the mean ± SEM of duplicate determinations from six rats. * = P < 0.05 
versus VEH+VEH control; # = P < 0.05 versus VEH+HAL group; £ = P < 0.05 versus VEH+CLZ group. 
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In this formula, the “numerator” calculates the reversal ef-
fect of pretreatment of QUI or DOI on the HAL-induced c-Fos 
expression (percent changes from the VEH+HAL level). The 
“denominator” calculates the intrinsic effect of pretreatment 
of QUI or DOI itself on the c-Fos expression (percent changes 
from the VEH+VEH level). For example, using this formula, we 
found that the pretreatment impact of QUI on HAL in the NAs 
was 0.89, whereas that of DOI was −0.42. The  ±  sign captured 
the opposite directions of QUI and DOI pretreatment impact 
on HAL. This pattern of QUI and DOI pretreatment impact 
could not have been revealed by simply examining their direct 
reversal effects on HAL. The overall results are summarized in 
Figure 7. As is evident, pretreatment of QUI and DOI produced 
opposite impacts on HAL- or CLZ-induced c-Fos expression 
in various brain regions (e,g, NAs, NAc, LSv, or DLSt). These 
dissociated pretreatment patterns were consistent with both 
our previous and present behavioral findings that only pre-
treatment of QUI (but not DOI) can reverse the HAL-induced 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
disruptions, whereas only pretreatment of DOI (but not QUI) 
can reverse the CLZ-induced deficits. Together with the find-
ings on the brain regions that showed increased c-Fos expres-
sion to HAL or CLZ treatment, it appears that the NAs, NAc, 
LSv and DLSt can be classified as the HAL neural system, 
whereas only the NAs should be considered as the CLZ neu-
ral system.
Discussion
The present study was built upon our recent work on the 
neurochemical basis of antipsychotic-induced disruptions of 
rat maternal behavior (Zhao and Li, 2009b). In that study, we 
administered QUI or DOI, together with HAL (0.2 mg/kg) or 
CLZ (10.0 mg/kg) to postpartum rats and examined which of 
these two agonists was able to reverse the disruptive effects 
induced by HAL or CLZ. We showed that pretreatment of 
QUI, but not DOI, dose-dependently improved the HAL-in-
duced disruptions of pup approach, pup retrieval, pup lick-
ing and nest building, whereas pretreatment of DOI, but not 
QUI, dose-dependently improved the CLZ-induced disrup-
tions of pup approach, pup retrieval and pup licking. The 
present study not only replicated these findings, but also 
showed that QUI or DOI treatment by itself also disrupted 
various components of maternal behavior. Rats treated with 
QUI or DOI retrieved fewer pups into the nest, spent less 
time on licking and nursing pups and on building nest. This 
finding is critically important because it suggests that the re-
versal effects of QUI on HAL and DOI on CLZ reflect the 
drug–drug interaction as opposed to the effect of a simple 
addition of individual drug, as both HAL and CLZ also dis-
rupted active maternal responses when given alone. On the 
basis of these findings, we suggest that the HAL-induced ma-
ternal deficits are primarily mediated by its blockade of D2 
dopamine receptors, whereas the CLZ-induced maternal def-
icits may be mediated by the blockade of 5-HT2A/2C recep-
tors. We recently confirmed the same double dissociation re-
ceptor mechanisms between HAL and CLZ in a conditioned 
avoidance response task (unpublished observation), a model 
predictive of antipsychotic activity (Li et al., 2007), suggest-
ing that the double dissociation of HAL and CLZ receptor 
mechanisms is closely related to their antipsychotic action, 
and is not task specific.
The most important finding of the present study is the 
identification of the distinct neural bases responsible for the 
maternal disruptive effects of HAL and CLZ. Our general 
strategy was to use c-Fos as a marker of neuronal activation 
to identify brain regions that show sensitive responses to the 
treatment of HAL or CLZ. Because we already know that 
pretreatment of QUI, but not DOI, reverses the HAL-induced 
maternal disruptions, whereas pretreatment of DOI, but not 
QUI, reverses the CLZ-induced ones (Zhao and Li, 2009b), 
to ensure that the identified systems are firmly grounded on 
this double dissociation receptor mechanisms and dissoci-
ated behavioral effects, we reasoned that the putative HAL 
neural system should also show sensitive responses to the 
reversal effects of QUI. In addition, it should show less or 
no c-Fos response to the pretreatment of DOI. Conversely, 
for the putative CLZ neural system, it should show sensi-
tive response to CLZ, and sensitive response to the reversal 
effects of DOI but not QUI. We carefully selected two clus-
Figure 7. Pretreatment impact of quinpirole or DOI on c-Fos expres-
sion induced by HAL and CLZ. (A) Impact (as expressed in “ratio”) of 
quinpirole or DOI pretreatment on HAL-induced c-Fos expression; (B) 
Impact (as expressed in “ratio”) of quinpirole or DOI pretreatment on 
CLZ-induced c-Fos expression. Percent change of direct effect of quin-
pirole or DOI (M) was calculated by subtracting the number of c-Fos 
positive cells (group mean) in the VEH+HAL or VEH+CLZ group (T) 
from the cell number in the quinpirole or DOI pretreatment group (e.g., 
QUI-1.0+HAL/CLZ or DOI-2.5+HAL/CLZ groups, P), dividing by cell 
number in the VEH+HAL or VEH+CLZ group [M = (P – T)/T]. Percent 
change of intrinsic effect of quinpirole or DOI (N) was calculated by 
subtracting the cell number in the VEH+VEH group (V) from the cell 
number in the VEH+QUI or VEH+DOI group (I), dividing by cell num-
ber in the VEH+VEH group [N = (I – V)/V]. Then pretreatment impact 
was obtained by M divided by NM/N. 
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ters of brain sites for c-Fos examination. One cluster includes 
brain regions that have been strongly implicated in the me-
diation of antipsychotic action, including the mPFC, NAs, 
NAc, DLSt and LSv (Binder et al., 2004; Guo et al., 1995; Mo et 
al., 2005; Robertson and Fibiger, 1992; Tremblay et al., 1998; 
Young et al., 1999). The second cluster includes brain regions 
that have been implicated in the mediation of rat maternal 
behavior, such as the NAs, MPOA, vBST and MeA (Bridges 
and Freemark, 1995; Li and Fleming, 2003a; Li and Fleming, 
2003b; Numan, 1988; Numan, 2007; Numan and Sheehan, 
1997; Numan and Stolzenberg, 2009; Numan et al., 2005). Of 
the eight brain regions examined, we found that only four 
(i.e. NAs, NAc, DLSt and LSv) met the criteria for the HAL 
neural system, and one (i.e. NAs) for the CLZ system. They 
all showed: (1) an increase in c-Fos expression in response 
to HAL or CLZ treatment; (2) a decrease in c-Fos expression 
in response to the reversal effects of pretreatment of QUI on 
HAL, or DOI on CLZ; and (3) opposing responses to the pre-
treatment of DOI on HAL or QUI on CLZ (see Figure 7). Ac-
cording to these criteria, the brain regions such as mPFC, 
LSv and vBST are not considered be part of the CLZ system 
despite the fact that they all showed increased c-Fos expres-
sion to CLZ treatment and have been implicated in the medi-
ation of maternal behavior (Afonso et al., 2007; Fleischer and 
Slotnick, 1978; Numan, 1994; Numan and Numan, 1995; Nu-
man and Numan, 1996). This is because they failed to meet 
all three criteria. However, this is not to say that they are not 
important for the expression of maternal behavior. It only 
means that CLZ most likely does not act on the 5-HT2A/2C re-
ceptors in these regions to achieve its disruption.
Action of HAL and CLZ in the NAs may account for their 
suppressive effect on maternal motivation (Zhao and Li, 2009a). 
Both D2 and 5-HT2A/2C receptors are richly expressed in the nu-
cleus accumbens, providing the neuroanatomical evidence for 
their action in this region (Clemett et al., 2000; Cornea-Hébert et 
al., 1999; Eberle-Wang et al., 1997; Mansour et al., 1990; Mengod 
et al., 1989; Mengod et al., 1990; Pompeiano et al., 1994). This 
finding is also consistent with a large number of studies indi-
cating that NA, especially the shell region, plays a key role in 
the modulation of rat maternal behavior (Hansen, 1994; Han-
sen et al., 1991a; Hansen et al., 1991b; Keer and Stern, 1999; Lee 
et al., 2000; Li and Fleming, 2003a; Li and Fleming, 2003b; Smith 
and Holland, 1975; Stolzenberg et al., 2007). Maternal interac-
tion with pups produced increased release of dopamine into 
the NA (Hansen et al., 1993), and increased c-Fos expression in 
the NAs (Lonstein et al., 1998; Stack et al., 2002). The effect of 
HAL on the DLSt and NAc has been suggested to mediate its 
EPS liability (Deutch et al., 1992; Fibiger, 1994; Robertson and 
Fibiger, 1992; Robertson et al., 1994), Thus, this action of HAL 
may be related to its motor impairment effect, which may also 
contribute its disruptive effect on active maternal responses at 
this dose (0.2 mg/kg). The LSv is a brain region that has also 
been implicated in rat maternal behavior. Previous studies 
show that lesions of LSv disrupt rat maternal behavior, as ev-
idenced by the lack of nest building and pup nursing due to 
the persistent disorganized pup retrieval (Fleischer and Slot-
nick, 1978; Numan, 1994). Together with the evidence showing 
that D2 receptors are expressed in the LSv (Mansour et al., 1990; 
Mengod et al., 1989), our finding supports that the D2 receptors 
in the LSv could also contribute to the HAL-induced disruption 
of maternal behavior.
We were surprised to learn that neither HAL nor CLZ alter 
c-Fos expression in the MPOA, vBNST and MeA, three critical 
brain regions that are directly involved in the regulation of rat 
maternal behavior (Kalinichev et al., 2000a; Numan, 1988; Nu-
man, 2007; Numan and Numan, 1996; Numan and Sheehan, 
1997). The lack of effect by HAL is understandable on the ba-
sis of findings that the MPOA D2 receptors are not critical for 
the expression of maternal behavior. Dopamine D2 receptor 
antagonists, such as raclopride and eticlopride failed to dis-
rupt maternal behavior, when infused directly into the MPOA 
(Miller and Lonstein, 2005; Numan et al., 2005). The lack of ef-
fect by CLZ may indicate that CLZ does not act on this hypo-
thalamic region to affect maternal behavior. This conclusion 
is tentative because even the vehicle control rats exhibited in-
creased c-Fos expression in the MPOA (Fleming et al., 1994; 
Kalinichev et al., 2000b; Lonstein et al., 1998; Numan and In-
sel, 2003; Stack and Numan, 2000; Stack et al., 2002), thus, the 
lack of strong CLZ treatment effects could have be masked by 
a ceiling effect. Our own unpublished observation suggests 
that the postpartum female rats did show increased c-Fos ex-
pression in the MPOA in comparison to the virgin females 
who were treated with HAL and CLZ but not exposed to rat 
pups. However, we think this ceiling effect explanation is not 
adequate because DOI treatment alone did increase c-Fos ex-
pression in the MPOA, suggesting that the level of c-Fos ex-
pression induced by HAL and CLZ had not reached the max-
imum level, and there is still room for HAL and CLZ to show 
an effect in this region.
We did notice that our control (VEH+VEH) animals had 
higher levels of c-Fos expression in the mPFC and NAs than 
those reported in other studies (Guo et al., 1995; Mo et al., 
2005; Robertson and Fibiger, 1992; Robertson et al., 1994). Sev-
eral factors may be contributable to such a relatively higher 
c-Fos expression. One factor is the effect of handling and in-
jection procedure stress. It has been well demonstrated that 
stress itself stimulates Fos expression in various brain re-
gions, such as the mPFC, LSv, vBST, MPOA and paraventric-
ular nucleus of the hypothalamus (PVH) (De Medeiros et al., 
2005; Monasterio et al., 2008; Senba and Ueyama, 1997). Our 
rats were behaviorally tested twice and injected three times 
before being sacrificed for c-Fos analysis. These manipula-
tions may have produced higher levels of stress and c-Fos ex-
pression. Another possible factor is the differences in method-
ology of c-Fos analysis. We counted the Fos-positive cells in a 
680×510 μm2 area of each region of a 40-μm section, while oth-
ers counted Fos-positive cells in a less small area and/or a less 
thin section at 30 μm (Guo et al., 1995; Mo et al., 2005; Robert-
son and Fibiger, 1992; Robertson et al., 1994). Future research 
including more control groups (e.g. virgin females, nonhan-
dled and noninjected, etc) is needed to sort out the different 
possibilities.
HAL-induced c-Fos expression is generally assumed to be 
attributed to its primary dopamine D2 receptor antagonism. 
The finding that QUI pretreatment reduced HAL-induced 
c-Fos increase in the NAs, NAc, DLSt and LSv is consistent 
with this hypothesis. The mechanisms underlying the CLZ-
induced c-Fos increase have not been fully delineated. It has 
been suggested that multiple receptor systems, such as D3, D4, 
adenosine A2A, β-adrenergic receptors, may be involved (Guo 
et al., 1995; Ohashi et al., 2000; Pinna et al., 1999; Vahid-Ansari 
and Robertson, 1996). Our findings that both DOI and QUI re-
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duced CLZ-induced c-Fos increase in the NAs are in agree-
ment with this idea. Although CLZ blocks multiple receptors, 
not all its receptor actions contribute to its therapeutic effects. 
In the case of maternal behavior, it appears that antagonistic 
action on the 5-HT2A/2C receptors in the NAs is more impor-
tant than others.
In addition to advancing our understanding of the neuroana-
tomical basis of action of HAL and CLZ, the present study also 
sheds new light on the neurochemical mechanisms involved in 
the regulation of normal expression of rat maternal behavior. 
Our results on the disruptive effects of QUI and DOI demon-
strated that the dopaminergic neurotransmission through D2/
D3 receptors and serotoninergic neurotransmission through 5-
HT2A/2C receptors are involved in the regulation of maternal 
behavior. These findings are consistent with the view suggest-
ing that dopamine transmission at a balanced level is neces-
sary for the normal display of maternal behavior, and if this 
transmission is either too low or too high disruptions will oc-
cur (Numan and Insel, 2003; Stern and Protomastro, 2000). The 
present results further expand this view by showing that a bal-
anced serotoninergic transmission is also critical for the normal 
expression of maternal behavior as both CLZ (which decreases 
5-HT neurotransmission) and DOI (which increases 5-HT neu-
rotransmission) disrupted maternal behaviors. Because DOI 
produced a broad increase in c-Fos expression in many fore-
brain regions that are implicated in rat maternal behavior, such 
as mPFC, NAs, NAc, MPOA and vBST, it suggests that sero-
toninergic transmissions in these regions are important for reg-
ulating maternal behavior.
Consistent with our recent work (Zhao and Li, 2009b), the 
present study provides pharmacological evidence supporting 
that 5-HT system is implicated in regulating rat maternal be-
havior based on the findings that systemic administration of 
DOI, a 5-HT2A/2C agonist, disrupts various components of rat 
maternal behavior (e.g., pup retrieval, pup licking, nest build-
ing and pup nursing). This finding is consistent with the grow-
ing literature. Brunner et al. (1999) reported that 5-HT1B re-
ceptor knockout mother mice did not display pup retrieval 
deficits. Other studies found that 5-HT1B and 5-HT2A/2C recep-
tors are involved in maternal aggressive behavior (De Almeida 
et al., 2005; De Almeida et al., 2006a; De Almeida et al., 2006b; 
Olivier et al., 1995; Veiga et al., 2007). Recently, Lerch-Haner 
et al. (2008) reported that transgenic mouse dams with a spe-
cific disruption in serotonin transcription factor displayed pro-
found maternal deficits (e.g., pup retrieval, pup nursing, nest 
building). Alenina et al. (2009) reported that the Tph2-deficient 
mouse dams lacking central serotonin exhibited disruptive ma-
ternal behavior as these dams neither retrieve their pups into 
the nest site nor nurturing them. Future work is required to ad-
dress the mechanisms through which serotonin system partici-
pates in the regulation of maternal behavior.
We should point out several limitations with the current re-
port. First, our search for the neural circuitries associated with 
the maternal behavioral effects of HAL and CLZ was largely 
a search within the brain regions associated either antipsy-
chotic treatment or with the mediation of maternal behavior. 
There is a possibility that brain regions outside these circuitries 
(e.g. ventral tegmental area) may also be involved. Second, our 
work is limited by the sensitivity of c-Fos immunohistochem-
istry. It is quite possible that the QUI-HAL and DOI-CLZ in-
teractions may produce brain changes that are unable to be de-
tected by c-Fos expression. Finally, our work is correlational 
in nature. Future research using the microinjection technique 
to directly administer drugs into different brain regions is re-
quired to confirm our findings on the specific HAL and CLZ 
neural systems.
Conclusion
The present study used the c-Fos immunohistochemistry tech-
nique, together with pharmacological tools and behavioral ob-
servations and delineated the neuroanatomical bases of the 
disruptive effects of haloperidol and clozapine on rat mater-
nal behavior. Our results show that the dopamine D2 receptor 
systems in the nucleus accumbens (both shell and core), dorso-
lateral striatum and lateral septum consist of the neural system 
that mediates the maternal disruptive effect of HAL. In con-
trast, the serotonin 5-HT2A/2C receptor system in the nucleus 
accumbens shell may be important for the maternal disruptive 
effect of CLZ.
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